ea0099ep423 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024
Del Prete Michela
, Eugenia Disoteo Olga
, Cozzi Renato
, Di Sacco Gianleone
, Vignati Federico
, Gavazzi Lidia
, Muratori Fabrizio
Introduction: The long acting GLP-1 analogue, Semaglutide (S), is indicated for the treatment of adults with type 2 diabetes mellitus (T2DM). Since November 2021, S has also been approved by the European Medicines Agency (EMA) at a dose of 2.4 mg for the treatment of obesity. Here, we report the efficacy of S, either alone or in combination with other antidiabetic drugs, in patients with T2DM and obesity on glycated hemoglobin (HBA1C) and weight loss.Pat...